- AstraZeneca has completed the commercialisation agreement with Aspen Global Inc under which AGI has acquired the residual rights to established anaesthetic medicines comprising of Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.

AstraZeneca initially entered an agreement with AGI in June 2016, under which AGI gained the exclusive commercialisation rights to the medicines in markets outside the US.

Under the terms of the new agreement which was announced on 14 Sep, AGI has now acquired the remaining rights to the intellectual property and manufacturing know-how related to the anaesthetic medicines.

Story provided by